GlassScriptPhysician profile
Lori Wheeler
NPI 1417483439
$5,145.46
in general payments reported to CMS, 2019-2025
16 companies · $1,914 in 2025
The $1,914 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,231 · 2025: $1,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,114 · Education: $31.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,114.40 |
| Education | $31.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $794.40 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $604.82 | 2024-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $603.15 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $590.45 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $514.97 | 2024-2025 | Lybalvi, Aristada |
| Abbvie INC. | $428.03 | 2024-2025 | |
| Lundbeck LLC | $366.05 | 2024-2025 | Rexulti |
| Corium, LLC | $261.28 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $258.09 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $248.09 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $199.33 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $104.30 | 2024-2025 | Trintellix |
| Neos Therapeutics, LP | $69.82 | 2025 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $53.64 | 2025 | Uzedy |
| Almatica Pharma LLC | $30.66 | 2024 | Loreev Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.38 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.